Talis Biomedical Corp
TLISDelisted Sep 20, 2024- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001584751
Talis Biomedical Corp was delisted on Sep 20, 2024; its insiders filed their last Form 4 on Sep 9, 2024; 18 institutions reported holding it in 13F filings for Q2 2024, worth $6.84M in total; Greenlight Capital was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 18
- Q2 2024, 0 vs. previous quarter
- 13F value
- $6.84M
- Reported value at the end of Q2 2024
- Superinvestors holding
- 1
- At the end of Q2 2024
Superinvestors holding TLIS, Q2 2024
1 superinvestor reports holding Talis Biomedical Corp on Form 13F. Percentages are the stock's share of each portfolio.
Greenlight Capital
David Einhorn
0.1%
Talis Biomedical Corp's share of the portfolio
- Shares
- 149,052
- Value
- $1.29M
Latest insider trades
Open-market purchases and sales by Talis Biomedical Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2024 (view filing) | Sep 5-6 | 4 days | Leonard Braden Michael10% Owner | PPurchase | +30.1K | $1.47 | +$44.1K | +13.8%248.7K after | 2 lots |
| Sep 5, 2024 (view filing) | Sep 3 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +500 | $4.00 | +$2.00K | +0.2%218.6K after | |
| Sep 4, 2024 (view filing) | Aug 30 | 5 days | Leonard Braden Michael10% Owner | PPurchase | +151 | $4.25 | +$641.75 | +0.1%218.6K after | |
| Aug 28, 2024 (view filing) | Aug 26-28 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +14.4K | $3.91 | +$56.2K | +7.1%218.0K after | 2 lots |
| Nov 19, 2021 (view filing)4:09 PM ET | Nov 18 | 1 day | Baker Julian and 5 othersDirector, 10% Owner | PPurchase | +50.0K | $4.37 | +$218.3K | +0.7%7.05M after | |
| Aug 17, 2021 (view filing) | Aug 13 | 4 days | Ramakrishnan RameshOther: Former Officer | SSale | −27.5K | $7.66 | −$210.7K | −41.6%38.6K after |
Top 10 13F holders, Q2 2024
The largest institutional positions in Talis Biomedical Corp at the end of Q2 2024; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 508,323 | $4.40M | 0.06% | 00.0% | Unchanged |
| DME Capital Management, LPSuperinvestorGreenlight Capital | 149,052 | $1.29M | 0.06% | 00.0% | Unchanged |
| BML Capital Management, LLC | 42,743 | $370.2K | 0.27% | 00.0% | Unchanged |
| Vanguard Group Inc | 31,013 | $268.6K | 0.00% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 14,928 | $129.3K | 0.01% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 14,020 | $123.4K | 0.00% | +2,130+17.9% | Added |
| Renaissance Technologies LLC | 12,299 | $106.5K | 0.00% | +2,000+19.4% | Added |
| Susquehanna International Group, LLP | 11,607 | $102.1K | 0.00% | −5,824−33.4% | Reduced |
| BlackRock Inc. | 4,271 | $37.0K | 0.00% | −440−9.3% | Reduced |
| Tower Research Capital LLC (TRC) | 877 | $7.60K | 0.00% | −50−5.4% | Reduced |